# Multicenter Study to Assess the Efficacy and Safety of Methyl Aminolevulinate Hydrochloride (MAL) 16.8% Cream (CD06809-41) Versus Vehicle Cream for Actinic Keratosis of the Face

> **NCT04085367** · PHASE3 · COMPLETED · sponsor: **Galderma R&D** · enrollment: 557 (actual)

## Conditions studied

- Actinic Keratoses

## Interventions

- **DRUG:** MAL 16.8% cream
- **DRUG:** MAL Vehicle Cream

## Key facts

- **NCT ID:** NCT04085367
- **Lead sponsor:** Galderma R&D
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-09-30
- **Primary completion:** 2021-03-03
- **Final completion:** 2021-04-07
- **Target enrollment:** 557 (ACTUAL)
- **Last updated:** 2022-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04085367

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04085367, "Multicenter Study to Assess the Efficacy and Safety of Methyl Aminolevulinate Hydrochloride (MAL) 16.8% Cream (CD06809-41) Versus Vehicle Cream for Actinic Keratosis of the Face". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04085367. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*